Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.
about
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancerA placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer.Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.Differentiated Thyroid Cancer-Treatment: State of the Art.rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic differentiated thyroid carcinomaDifferences in physicians' and patients' perception of acute hypothyroid symptoms induced by thyroid hormone withdrawal in thyroid cancer patients: a multicenter survey in Korea.Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective.Long-term results after treatment of very low-, low-, and high-risk thyroid cancers in a combined setting of thyroidectomy and radio ablation therapy in euthyroidism.Expanding indications for recombinant human TSH in thyroid cancerPediatric papillary thyroid cancer: current management challengesIn thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review.Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.Health-related quality of life among thyroid cancer survivors: a systematic review.Radioiodine for remnant ablation and therapy of metastatic disease.Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing-related increases in body mass in thyroid cancer survivors.Differentiated thyroid cancer-personalized therapies to prevent overtreatment.Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic DiseaseAdjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer.Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.Comparing the effectiveness of stimulation using rhTSH and thyroid hormone withdrawal in the treatment of thyroid cancer.Short-term severe thyroid hormone deficiency does not influence sleep parameters.Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management.Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.
P2860
Q24236576-EB321EFD-0288-4B75-80C9-FCF54964CBEFQ33597636-8727930A-28AA-49A1-A3F6-1586A6E3ECE9Q33759426-49FC7737-F23F-4FB4-90CE-6654E236AE9AQ33839037-6591979C-1F8C-42FF-BF47-950529566CFEQ34985318-1A602BD5-F519-4694-B847-6E0CC2B3A20CQ35173247-BC9C65C3-BE99-45EE-A6D5-B4C1EE3BAA34Q35507298-9453BC75-6B7D-43FB-B6AC-ECD92A03F9D2Q36489166-A47765AD-E7B6-4DC4-B14E-33E4453E563EQ37045228-34753489-5B7E-4BE6-B915-D73CD394C62BQ37087770-2E84B8B7-4B0C-43FD-A72B-AF9F58B2DE47Q37551856-F4EA7E9A-2E03-4C59-93D0-FA4DAF224E37Q37573792-19981C87-3412-454D-8ECF-FE5AC9FC5174Q37622758-4F7851B8-F674-4D41-8136-2120514A5852Q37815386-FF242C68-0AA1-4BF7-8623-B7CBF0161D0DQ37880184-8BF36E11-27EB-445D-92CD-DB3940CB80ADQ37913996-CF85A724-FF42-429A-9C1A-7DC61C1A15E3Q37946468-D41040A3-C4B3-4E91-B55A-E12CE559B861Q38224994-81E5FB75-4342-49B6-9E96-7136DE29AA9EQ38591767-FEE7F447-1A6D-4B74-8D69-14C49EB2B3A0Q42162040-97A64200-97F6-4E16-90AC-F2AE7288DB27Q42427139-3AAD97C6-4676-4620-8D3D-387D0357C508Q42478263-B5903E5C-85ED-4933-8DE9-535677FAFE84Q45977788-1A9DB2A2-CE4B-45DD-8E48-9C77748E1071Q46385544-48D2D18D-805F-4B21-8B12-B7F2B05CEF91Q48557941-A206A131-EF2E-4DC4-AA46-977650699CBCQ53308051-F45AFD65-7330-4D99-A07F-AF30DB950C9F
P2860
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@en
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@nl
type
label
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@en
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@nl
prefLabel
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@en
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@nl
P2093
P356
P1433
P1476
Thyroid hormone withdrawal in ...... nt thyrotropin administration.
@en
P2093
Christoph Reiners
Markus Dietlein
Markus Luster
Ralph Felbinger
P304
P356
10.1089/THY.2005.15.1147
P577
2005-10-01T00:00:00Z